Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database

BackgroundMepolizumab, a monoclonal antibody targeting interleukin-5, is used to treat severe eosinophilic asthma and other eosinophilia-related conditions. Given its growing use, there is a pressing need for the latest data to improve the understanding and management of its adverse events (AEs). Th...

Full description

Bibliographic Details

Published in:	Frontiers in Medicine
Main Authors:	Shan Lin, Dachen Luo, Zonglian Gong, Qingyuan Zhan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-10-01
Subjects:	mepolizumab asthma adverse events pharmacovigilance FAERS
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2024.1449194/full